These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35966167)

  • 1. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.
    Florez MA; Kemnade JO; Chen N; Du W; Sabichi AL; Wang DY; Huang Q; Miller-Chism CN; Jotwani A; Chen AC; Hernandez D; Sandulache VC
    Cancer Res Commun; 2022 Jul; 2022(8):806-13. PubMed ID: 35966167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
    Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
    Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
    Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
    Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
    Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
    Chen S; Yang Y; Wang R; Fang J
    Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer.
    Fukuoka O; Saito Y; Mukai T; Hayashi T; Yamamura K; Sakai T; Kobayashi K; Akashi K; Yoshida M; Ando M; Yamasoba T
    Laryngoscope; 2024 Jan; 134(1):228-235. PubMed ID: 37377185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
    Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
    Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
    Liu T; Li Q; Lin Z; Wang P; Chen Y; Fu Y; Ding Z
    Int Immunopharmacol; 2021 Nov; 100():108128. PubMed ID: 34537483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
    Vienne A; Collet L; Chevalier T; Borel C; Tardy M; Huguet F; Richard S; Salas S; Saada-Bouzid E; Fayette J; Daste A
    BMC Cancer; 2023 Jul; 23(1):663. PubMed ID: 37452287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.